UGT1A1 and gastric cancer: Sharma et al. [18] also conducted a phase I study of FOLFIRINOX for pancreatic, biliary and gastric cancer patients with homozygous only for UGT1A1*28 and showed a high frequency of adverse events, such as neutropenia; they concluded that irinotecan 90 mg/m2 cannot be considered as the recommended dose.